Loading…
Lobbying Spend
—
Filings
82
Firms Hired
2
Active Period
2014–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
American Rescue Plan Act of 2021
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
Medicaid Drug Rebate Program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid Value Based Payment rule H.R. 1319, American Rescue Plan of 2021 implementation
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1319
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7667
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
American Rescue Plan Act of 2021
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
Medicaid Drug Rebate Program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid Value Based Payment rule H.R. 1319, American Rescue Plan of 2021 implementation
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1319
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7667
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
American Rescue Plan Act of 2021
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
Medicaid Drug Rebate Program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid Value Based Payment rule H.R. 1319, American Rescue Plan of 2021 implementation
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1319
American Rescue Plan Act of 2021
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1319
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 6833, Continuing Appropriations and Ukraine Supplemental Appropriations Act of 2023
Client expense: — · Firm income: $80,000
Matched citations: H.R. 6833
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7667
H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
American Rescue Plan Act of 2021
2022 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
Medicaid Drug Rebate Program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid Value Based Payment rule H.R. 1319, American Rescue Plan of 2021 implementation
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1319
American Rescue Plan Act of 2021
2022 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Build Back Better Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1319
Consolidated Appropriations Act, 2022
2022 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2471, Consolidated Appropriations Act 2022 reconciliation
Client expense: — · Firm income: $80,000
Matched citations: H.R. 2471
Inflation Reduction Act of 2022
2022 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Build Back Better Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Food and Drug Amendments of 2022
2022 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Build Back Better Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7667
H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Build Back Better Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
American Rescue Plan Act of 2021
2022 · first_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy H.R. 1319, American Rescue Plan of 2021 implementation H.R. 5376, the Build Back Better Act
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1319
Source: Senate LDA